TwinEdge Bioscience Appoints Dr. Bulak Arpat as Chief Operating Officer

TwinEdge Bioscience is excited to announce the appointment of Dr. Bulak Arpat as its new Chief Operating Officer (COO).

Dr. Arpat joins TwinEdge with a distinguished background in computational biology, bringing deep expertise from over 20 years spent both in academia and industry. His appointment marks a significant step forward in TwinEdge’s mission to transform decision-making in oncology drug development.

Prior to joining TwinEdge, Dr. Arpat was Director of In silico Drug Development at JSR Life Sciences, where he led a cross-functional team overseeing the development of translational and predictive tools using multiomic datasets. He is known for his ability to bridge science and strategy, with a focus on impact, scalability, and execution.

“TwinEdge is really revolutionising how decisions are made in Translational and Clinical oncology, and I’m delighted to have the opportunity to help build such a unique and impactful company,” said Dr. Arpat.

In his role as COO and Co-Founder, Dr. Arpat will lead company operations, drive execution across R&D and strategic initiatives, and partner closely with both industry clients and strategic partners. 

“Bulak’s unique blend of scientific insight and operational rigor makes him the ideal leader to help guide TwinEdge through its next phase of growth,” said Mike Prosser, CEO of TwinEdge Bioscience. “We’re thrilled to welcome him to the team.”

Please join us in welcoming Dr. Bulak Arpat to TwinEdge Bioscience.